ICD-10-CM Code for Triple-Negative Breast Cancer
The ICD-10-CM code for triple-negative breast cancer is C50.x (malignant neoplasm of breast), with the specific fourth digit determined by the anatomical location of the tumor within the breast.
Understanding the Coding Structure
Triple-negative breast cancer (TNBC)—defined as breast cancer that is estrogen receptor-negative, progesterone receptor-negative, and HER2-negative 1—does not have a unique, dedicated ICD-10-CM code that distinguishes it from other breast cancer subtypes. Instead, you must use the standard breast cancer codes with anatomical site specification:
Primary Code Selection
- C50.0 - Malignant neoplasm of nipple and areola
- C50.1 - Malignant neoplasm of central portion of breast
- C50.2 - Malignant neoplasm of upper-inner quadrant of breast
- C50.3 - Malignant neoplasm of lower-inner quadrant of breast
- C50.4 - Malignant neoplasm of upper-outer quadrant of breast
- C50.5 - Malignant neoplasm of lower-outer quadrant of breast
- C50.6 - Malignant neoplasm of axillary tail of breast
- C50.8 - Malignant neoplasm of overlapping sites of breast
- C50.9 - Malignant neoplasm of breast, unspecified
Laterality Specification
Each code requires a fifth digit for laterality:
- 1 = Right breast
- 2 = Left breast
- 9 = Unspecified side
Example: For triple-negative breast cancer in the upper-outer quadrant of the right breast, use C50.411.
Clinical Context for Accurate Coding
While the ICD-10-CM system does not distinguish TNBC from other breast cancer subtypes in the primary diagnosis code, understanding the clinical characteristics is essential for comprehensive documentation 1:
- TNBC represents 10-20% of invasive breast cancers
- Peak recurrence risk occurs within 3 years of diagnosis
- More common in African-American women, premenopausal women, and those with BRCA1 mutations
- Associated with higher grade, more advanced stage, and poorer prognosis compared to hormone receptor-positive subtypes
Documentation Best Practices
To ensure accurate coding and capture the triple-negative status:
- Use the anatomically specific C50.x code as the primary diagnosis
- Document the receptor status separately in the medical record (ER-negative, PR-negative, HER2-negative)
- Include histologic grade and stage using appropriate additional codes
- Consider adding Z codes for genetic susceptibility if BRCA1/2 mutations are present (Z15.01 for BRCA1, Z15.02 for BRCA2)
Common Pitfall to Avoid
Do not use C54.x codes (malignant neoplasm of corpus uteri/endometrium), as these are for uterine cancers, not breast cancers. This distinction is critical, as validation studies have shown the importance of using correct anatomical site codes for accurate cancer case identification 2, 3.
The lack of a specific TNBC code in ICD-10-CM reflects the coding system's focus on anatomical location rather than molecular subtype. However, the triple-negative designation remains clinically crucial for treatment planning, as TNBC requires different therapeutic approaches—primarily chemotherapy and immunotherapy rather than hormone-targeted therapies 4, 5.